Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit
Trio Of Generics Manufacturers Named In 2021 Suit Which Alleges Conspiracy Over Colchicine
Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.
You may also be interested in...
Endo’s Par has moved on the first FDA-approved generic version of Hikma’s Mitigare prevention of gout flares – weeks after another ANDA sponsor, Micro Labs, sought to clear its own path to market via a lawsuit.
Endo has realised plans to launch an authorised generic of Takeda’s Colcrys (colchicine) 0.6mg tablets through its Par Pharmaceutical subsidiary, under a prior US supply and distribution agreement involving the Endo Ventures affiliate.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.